2016, Número 4
<< Anterior Siguiente >>
Ann Hepatol 2016; 15 (4)
Meta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B
He M, Wu Y, Wang M, Chen W, Jiang J
Idioma: Ingles.
Referencias bibliográficas: 27
Paginas: 482-491
Archivo PDF: 175.64 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85 [PubMed: 22436845].
Liaw YF. Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia. J Hepatol 2009; 51: 403-10 [PubMed: 19467727].
Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J Viral Hepat 2010; 17: 10-7 [PubMed: 20586929].
Lu LG, Zeng MD, Mao YM, Fang JY, Song YL, Shen ZH, Cao AP. Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice. World J Gastroenterol 2004; 10: 1176-9 [PubMed: 15069721].
Xu WS, Zhao KK, Miao XH, Ni W, Cai X, Zhang RQ, Wang JX. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol 2010; 16: 2028-37 [PubMed: 20419842].
Lu LG, Zeng MD, Mao YM, Li JQ, Wan MB, Li CZ, Chen CW, et al. Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multicenter trial. World J Gastroenterol 2003; 9: 2480-3 [PubMed: 14606080].
Mao YM, Zeng MD, Lu LG, Wan MB, Li CZ, Chen CW, Fu QC, et al. Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo- controlled, multicenter clinical study. World J Gastroenterol 2004; 10: 3269-73 [PubMed: 15484298].
Jin XH, Wang YG. Cost effectiveness analysis of three methods in the treatment of chronic viral hepatitis B. Strait Pharmaceutical J 2008; 20: 139-40. Available at: http:// epub.cnki.net/kns/brief/result.aspx?dbPrefix=CJFQ
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12 [PubMed: 8721797].
Huang YQ, Lin ZH, Ji SM, Xu ZJ, Wang CG. Clinical study of the interferon α-2b combined with oxymatrine in the treatment of chronic hepatitis B. Chin J Infect Dis 2004; 22: 259- 262. Available at: Available at: http://epub.cnki.net/kns/brief/ result.aspx?dbPrefix=CJFQ
Li WH. Clinical study of Interferon-a combined with oxymatrine in the treatment of patients with HbeAg- positive hepatitis B. J Prac Hepatol 2014; 17: 186-7. Available at: http://epub.cnki.net/kns/brief/result.aspx?dbPrefix=CJFQ
NuEGL YBLYM. Clinical study of the interferon combined with oxymatrine in the treatment of chronic hepatitis B. Chinese Community Doctors 2011; 13: 214. Available at: http:// epub.cnki.net/kns/brief/result.aspx?dbPrefix=CJFQ
OuYang GS. Clinical study of Interferon combined with oxymatrine in the treatment of patients with HbeAg- positive hepatitis B. National Medical Frontiers of China 2011; 6: 17-8. Available at: http://epub.cnki.net/kns/brief/result.aspx? dbPrefix= CJFQ
Qin ZX, Zhang GC, Wang L, Zhu SF. Kushenin in combination with α-2b interferon for chronic hepatitis B: Observation of prospective efficacy. J Chinese Physician 2006; 18: 858-9. Available at: http://epub.cnki.net/kns/brief/result.aspx?dbPrefix=CJFQ
Shi YZ, Li CX. Clinical study of the interferon combined with oxymatrine in the treatment of chronic hepatitis B. Clinical Medicine of China 2004; 20: 417-8. Available at: http:// epub.cnki.net/kns/brief/result.aspx?dbPrefix=CJFQ
Shi ZJ, Zhang HT, Zhang XY. Kushenin in Combination with α-2b Interferon for chronic hepatitis B: Observation of Curative Efficacy. China Pharmacy 2007; 18: 2139-40. Available at: http://epub.cnki.net/kns/brief/result.aspx? dbPrefix =CJFQ
Wen XM. Clinical study of the interferon α-2b combined with oxymatrine in the treatment of chronic hepatitis B. Secondary Medical Education 2003; 21: 136-7. Available at: http:// epub. cnki .net/ kns/brief/ result.aspx?dbPrefix =CJFQ
Yu JG. Clinical study of the interferon a-2a combined with oxymatrine in the treatment of chronic hepatitis B. Chinese Hepatology 2013; 18: 205-6. Available at: http://epub.cnki. net/kns/brief/result.aspx?dbPrefix=CJFQ
Zhang XD, Sun MZ, Li XF, Liu ZJ. Observation of the therapeutic effects of interferon combined with Kushenin in the treatment of chronic hepatitis B. China Pharmacy 2005; 16: 450-1. Available at: http://epub.cnki.net/kns/brief/result.aspx ?dbPrefix=CJFQ
Zhao WL, Hu QM, Yang ZM, Zhang W. Clinical study of Interferon- α combined with oxymatrine in the treatment of patients with chronic hepatitis B. Journal of Yangtze University (Natural Science Edition) Medicine V 2007; 4: 161-2. Available at: http://epub.cnki.net/kns/brief/result.aspx?dbPrefix=C JFQ
Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 2010; 4: 39-47 [PubMed: 20448340].
Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, You XF, et al. Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus. Antimicrob Agents Chemother 2010; 54: 2070-7 [PubMed: 20176893].
Wang YP, Zhao W, Xue R, Zhou ZX, Liu F, Han YX, Ren G, et al. Oxymatrine inhibits hepatitis B infection with an advantage of overcoming drug-resistance. Antiviral Res 2011; 89: 227-31 [PubMed: 21277330].
Yao N, Wang X. In vitro immunomodulatory activity of oxymatrine on toll-like receptor 9 signal pathway in chronic hepatitis B. Am J Chin Med 2014; 42: 1399-410 [PubMed: 25406654].
Chai NL, Fu Q, Shi H, Cai CH, Wan J, Xu SP, Wu BY. Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells. World J Gastroenterol 2012; 18: 4199-206 [PubMed: 22919254].
Dong YH, Xi HL, Tian F, Kang AJ, Zhang NL, Yu M, Yu YY, et al. Effects of oxymatrine on serum levels of Th1/Th2 type cytokines in HBsAg transgenic mice. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2004; 18: 277-80 [PubMed: 15640867].
Gu XB, Yang XJ, Hua Z, Lu ZH, Zhang B, Zhu YF, Wu HY, et al. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B. Chin Med J (Engl) 2012; 125: 1434-8 [PubMed: 22613649].